Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 35,371 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Infertility
Interventions: Midcycle ultrasound + hCG injection, Urinary LH kits; Other
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 39 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Depression, Insomnia
Interventions: Cognitive Behavioral Therapy for Insomnia, Cognitive Behavioral Therapy for Depression, Mood Monitoring; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 1,175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Bronchopulmonary Dysplasia (BPD)
Interventions: Metformin (open-label); Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 7 Days to 6 Months
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Clinical Stage III Nodal or Intransit Disease or Resectable Stage IV Melanoma
Interventions: FDG PET/CT imaging; Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Abuse, Child, Crying, Parent-Child Relations
Interventions: Take 5 and Audio Clip, Take 5 Only; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hemophilia A
Interventions: Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 6 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 17
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more

Conditions: Healthy Volunteers
Interventions: LY2623091; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Unresectable Melanoma, Metastatic Melanoma
Interventions: Nivolumab, Ipilimumab, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 19
States / cities: San Francisco, California • Orlando, Florida • Louisville, Kentucky + 13 more

Conditions: Endometriosis
Interventions: Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix, Placebo for E2/NETA; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 681 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 188
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more

Conditions: Diabetic Foot Ulcers
Interventions: V.A.C. Negative Pressure Wound Therapy System; Device
Lead sponsor: KCI USA, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 6
States / cities: New Haven, Connecticut • South Miami, Florida • Bethlehem, Pennsylvania + 2 more

Conditions: Epidermolysis Bullosa
Interventions: Alwextin cream; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 6 Months and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
Interventions: Miricorilant, Fluvoxamine; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Metastatic Cancer
Interventions: Checkpoint blockade immunotherapy, Checkpoint blockade immunotherapy plus SBRT; Drug · Radiation
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Migraine Disorders, Refractory Migraine, Chronic Migraine
Interventions: TEMMA Endovascular Treatment; Device
Lead sponsor: Cortex Neurovascular; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2032
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Atrial Fibrillation
Interventions: Pulmonary vein antrum isolation (PVAI), PVAI plus left atrial posterior wall (LAPW) isolation; Procedure
Lead sponsor: Texas Cardiac Arrhythmia Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Rectal Cancer
Interventions: Cetuximab, 5-fluorouracil, Pelvic irradiation; Drug · Radiation
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 41
States / cities: Tucson, Arizona • Melbourne, Florida • Miami, Florida + 36 more

Conditions: Healthy
Interventions: Virtual Promotoras Program; Behavioral
Lead sponsor: University of Alabama, Tuscaloosa; Other
Eligibility: 16 Years to 21 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tuscaloosa, Alabama

Conditions: Periodontitis, Periodontal Diseases
Interventions: metronidazole; Drug
Lead sponsor: The Forsyth Institute; Other
Eligibility: 35 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Body Dysmorphic Disorders
Interventions: None, observational study only (no interventions); Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Beta Haemolytic Streptococcal Infection
Interventions: GBS III-TT, Tetanus and diptheria toxoids vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Augusta, Georgia • Pittsburgh, Pennsylvania • Houston, Texas

Conditions: HPV Vaccine, HPV
Interventions: Online survey, Focus groups or Individual Interviews, Interviews; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Gynecologic Neoplasms, Epithelial Ovarian Cancer
Interventions: PLX2853, Carboplatin; Drug
Lead sponsor: Opna Bio LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 5 more

Conditions: Asthma, Insomnia
Interventions: SHUTi, Emmi; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, End Stage Renal Disease
Interventions: Adipose tissue biopsy; Procedure
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Galveston, Texas

Search by objective public record fields.

Use of High Cost Monitoring During Letrozole Ovulation Induction

Digital CBT for Insomnia and Depression

Metformin for Premature Infants With Bronchopulmonary Dysplasia

Early FDG PET in Melanoma

Take 5 + Audio Clip Randomized Control Trial

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

A Study of How the Body Breaks Down and Eliminates LY2623091

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negative Pressure Wound Therapy

Study of Alwextin® Cream in Treating Epidermolysis Bullosa

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease

EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization

Outcome of Atrial Fibrillation Ablation After Permanent Pulmonary Vein Antrum Isolation With or Without Proven Left Atrial Posterior Wall Isolation

Pre-op Rectal ChemoRad +/- Cetuximab

The Virtual Promotoras Study: eHealth Intervention to Promote Sexual Health Among Young Latina Women in the US South

Microbial Associations in Periodontal Health and Disease

Understanding Daily Changes in BDD Risk Using Smartphones

Prevention of GBS Colonization Via Immunity

Adaptation Of An HPV Education Resource To Promote HPV Vaccination

PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

Solving Insomnia Electronically: Sleep Treatment for Asthma

Adipose Tissue Function After Pancreas Transplantation